ADPS™
KRAS G12C Mutation Test Kit
Improve KRAS G12C Research Outcomes with Ultra-Sensitivity
Improve KRAS G12C Research Outcomes with Ultra-Sensitivity
KRAS mutations are common oncogenic mutations in various cancers. They occur in approximately 30% of non-small cell lung cancer (NSCLC) and approximately 47% of colorectal cancer (CRC). Specifically, KRAS G12C mutations are found in approximately 13% of lung adenocarcinomas, 3% of colorectal cancers, and at levels of 1% to 2% in several other solid tumors. KRAS G12C is a single-base mutation from glycine to cysteine occurring in codon 12.
This mutation favors the active state of KRAS, amplifying signaling pathways that drive oncogenesis. The KRAS G12C mutation is found in NSCLC, and Sotorasib (LUMAKRAS™) is a novel small molecule that specifically inhibits KRAS G12C. It traps the KRAS protein in an inactive state by binding to the inactive GDP-bound conformation. Diagnosis of KRAS G12C mutations in NSCLC patients may guide treatment with Sotorasib.
The ADPS™ KRAS G12C Mutation Test Kit detects the KRAS G12C mutation with a high sensitivity of 0.02%. It is designed for testing both tissue and plasma samples with a single kit.
This product is for research use only (RUO) and not intended for use in diagnostic procedures.
| Catalog No. | (RUO) R8007APA |
|---|---|
| Detection target | KRAS G12C |
| Assay type | qPCR |
| Sample type | DNA extracted from FFPE, frozen, and fresh cancer tissue or liquid biopsy |
| Master Mixture (MMX) |
1MMX |
| Internal Control | KRAS intron 4 |
| Detection Sensitivity | 0.02% |
| Detection Specificity | ≥ 99% |
| Precision (% CV) | ≤ 5% (CV, coefficient of variation) |
| Storage | -20±5℃ |
| Stability | 18 months |
| Freeze/Thaw stability | 5 times |
| Compatible Instruments | AB 7500 Fast, CFX96, QuantStudio 5 |
ADPS™ Oncogene Mutation Test